{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:26:14Z","timestamp":1683073574976},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2008,2,15]],"date-time":"2008-02-15T00:00:00Z","timestamp":1203033600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmologe"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1007\/s00347-007-1639-1","type":"journal-article","created":{"date-parts":[[2008,2,13]],"date-time":"2008-02-13T16:14:16Z","timestamp":1202919256000},"page":"650-655","source":"Crossref","is-referenced-by-count":8,"title":["Die Rolle des Stratus-OCT bei der Anti-VEGF-Therapie"],"prefix":"10.1007","volume":"105","author":[{"given":"M.","family":"Bolz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ritter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Polak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Ahlers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Hirn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Pr\u00fcnte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Golbaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Benesch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Schmidt-Erfurth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,2,15]]},"reference":[{"key":"1639_CR1","first-page":"1621","volume":"11","author":"Bressler","year":"2003","unstructured":"Bressler NM, Bressler SB, Congdon NG et al. (2003) Potential public health impact of age-related eye disease study results: AREDS report no. 11. Arch Ophthalmol 11: 1621\u20131624","journal-title":"Arch Ophthalmol"},{"key":"1639_CR2","first-page":"A17","volume":"3","author":"Gohdes","year":"2005","unstructured":"Gohdes DM, Balamurugan A, Larsen BA et al. (2005) Age-related eye diseases: an emerging challenge for public health professionals. Prev Chronic Dis 3: A17","journal-title":"Prev Chronic Dis"},{"key":"1639_CR3","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ajo.2003.11.069","volume":"3","author":"Klein","year":"2004","unstructured":"Klein R, Peto T, Bird A et al. (2004) The epidemiology of age-related macular degeneration. Am J Ophthalmol 3: 486\u2013495","journal-title":"Am J Ophthalmol"},{"key":"1639_CR4","doi-asserted-by":"crossref","unstructured":"Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 4: 581\u2013611","DOI":"10.1210\/er.2003-0027"},{"key":"1639_CR5","first-page":"855","volume":"5","author":"Lopez","year":"1996","unstructured":"Lopez PF, Sippy BD, Lambert HM et al. (1996) Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 5: 855\u2013868","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1639_CR6","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1006\/mvre.2002.2407","volume":"1","author":"Otani","year":"2002","unstructured":"Otani A, Takagi H, Oh H et al. (2002) Vascular endothelial growth factor family and receptor expression in human choroidal neovascular membranes. Microvasc Res 1: 162\u2013169","journal-title":"Microvasc Res"},{"key":"1639_CR7","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1001\/archopht.120.3.338","volume":"3","author":"Krzystolik","year":"2002","unstructured":"Krzystolik MG, Afshari MA, Adamis AP et al. (2002) Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 3: 338\u2013346","journal-title":"Arch Ophthalmol"},{"key":"1639_CR8","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.ophtha.2005.01.043","volume":"6","author":"Rosenfeld","year":"2005","unstructured":"Rosenfeld PJ, Schwartz SD, Blumenkranz MS et al. (2005) Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 6: 1048\u20131053","journal-title":"Ophthalmology"},{"key":"1639_CR9","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.ophtha.2005.10.052","volume":"113","author":"Heier","year":"2006","unstructured":"Heier JS, Antoszyk AN, Pavan PR et al. (2006) Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I\/II multicenter, controlled, multidose study. Ophthalmology 113: 642.e1\u20134","journal-title":"Ophthalmology"},{"key":"1639_CR10","first-page":"361","volume":"3","author":"Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Rich RM, Lalwani GA (2006) Ranibizumab: Phase III clinical trial results. Ophthalmol Clin North Am 3: 361\u2013372","journal-title":"Ophthalmol Clin North Am"},{"key":"1639_CR11","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"14","author":"Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS et al. (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 14: 1419\u20131431","journal-title":"N Engl J Med"},{"key":"1639_CR12","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1177\/019262339902700507","volume":"5","author":"Mordenti","year":"1999","unstructured":"Mordenti J, Cuthbertson RA, Ferrara N et al. (1999) Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 5: 536\u2013544","journal-title":"Toxicol Pathol"},{"key":"1639_CR13","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1167\/iovs.03-0514","volume":"6","author":"Paunescu","year":"2004","unstructured":"Paunescu LA, Schuman JS, Price LL et al. (2004) Reproducibility of nerve fiber thickness, macular thickness, and optic nerve head measurements using StratusOCT. Invest Ophthalmol Vis Sci 6: 1716\u20131724","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1639_CR14","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/00061198-200406000-00012","volume":"3","author":"Gurses-Ozden","year":"2004","unstructured":"Gurses-Ozden R, Teng C, Vessani R et al. (2004) Macular and retinal nerve fiber layer thickness measurement reproducibility using optical coherence tomography (OCT-3). J Glaucoma 3: 238\u2013244","journal-title":"J Glaucoma"},{"key":"1639_CR15","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ophtha.2005.10.005","volume":"2","author":"Sadda","year":"2006","unstructured":"Sadda SR, Wu Z, Walsh AC et al. (2006) Errors in retinal thickness measurements obtained by optical coherence tomography. Ophthalmology 2: 285\u2013293","journal-title":"Ophthalmology"}],"container-title":["Der Ophthalmologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-007-1639-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00347-007-1639-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-007-1639-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T13:50:49Z","timestamp":1559051449000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00347-007-1639-1"}},"subtitle":["Qualitative und quantitative Beurteilung bei neovaskul\u00e4rer AMD"],"short-title":[],"issued":{"date-parts":[[2008,2,15]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["1639"],"URL":"https:\/\/doi.org\/10.1007\/s00347-007-1639-1","relation":{},"ISSN":["0941-293X","1433-0423"],"issn-type":[{"value":"0941-293X","type":"print"},{"value":"1433-0423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2,15]]}}}